Cyteir Therapeutics
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
You can watch CYTT and buy or sell other stocks, ETFs, and their options commission-free!About CYTT
Cyteir Therapeutics, Inc.is a clinical-stage biotechnology company, develops and commercializes the next-generation of precision oncology medicines. Its lead product CYT-0851, a novel, oral, once-daily, small molecule drug candidate that is in Phase I/II clinical trial for monotherapy in solid tumors and hematologic malignancies, as well as for combination therapy in solid tumors and hematologic malignancies.
CEOMarkus F. Renschler, MD
CEOMarkus F. Renschler, MD
Employees—
Employees—
HeadquartersLexington, Massachusetts
HeadquartersLexington, Massachusetts
Founded2012
Founded2012
Employees—
Employees—
CYTT Key Statistics
Market cap108.35M
Market cap108.35M
Price-Earnings ratio-3.23
Price-Earnings ratio-3.23
Dividend yield—
Dividend yield—
Average volume645.29K
Average volume645.29K
High today—
High today—
Low today—
Low today—
Open price—
Open price—
Volume0.00
Volume0.00
52 Week high$3.19
52 Week high$3.19
52 Week low$1.65
52 Week low$1.65
Stock Snapshot
As of today, Cyteir Therapeutics(CYTT) shares are valued at $3.01. The company's market cap stands at 108.35M, with a P/E ratio of -3.23.
On 2025-12-10, Cyteir Therapeutics(CYTT) stock opened at —, reached a high of —, and a low of —.
The Cyteir Therapeutics(CYTT)'s current trading volume is 0, compared to an average daily volume of 645.29K.
In the last year, Cyteir Therapeutics(CYTT) shares hit a 52-week high of $3.19 and a 52-week low of $1.65.
In the last year, Cyteir Therapeutics(CYTT) shares hit a 52-week high of $3.19 and a 52-week low of $1.65.
People also own
Based on the portfolios of people who own CYTT. This list is generated using Robinhood data, and it’s not a recommendation.